Johnson & Johnson CEO Joaquin Duato says the company can realistically cure certain cancers within the next decade. Duato makes the comments at a CEO summit in London, where he also discusses the company’s innovation efforts. He adds that artificial intelligence is already helping J&J develop medicines faster. The remarks are framed as long-term targets tied to ongoing research and development capabilities rather than specific therapies or timelines for individual cancer types. Neither source provides detailed information about which cancers Duato is referring to, what “cure” means in measurable clinical terms, or whether the goal depends on particular treatment approaches or regulatory milestones. Overall, the statements connect J&J’s cancer ambitions to advancements in medicine development, including the use of AI to accelerate aspects of drug discovery and development.